Larvol Delta - Costeffectiveness-analysis-of-Atezolizumab-plus-bevacizumab-vs-Rivoceranib-plus-Camrelizumab-as-firstline-treatment-for-unresectable-hepatocellular-carcinoma

AiTan (rivoceranib) - Elevar Therapeutics

Tecentriq (atezolizumab) - Roche

Avastin (bevacizumab) - Roche

AiRuiKa (camrelizumab) - Elevar Therapeutics

http://www.ncbi.nlm.nih.gov/pubmed/42326932

Mengmeng Liu; Tong Liu

Jun 23, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next